Cognitive
By Samir Levin · June 4, 2026 · 5 min read
Cerebrolysin occupies a unique position in the cognitive enhancement landscape: it is the only neuropeptide preparation with clinical evidence of neurotrophic activity comparable to endogenous nerve growth factor (NGF). That is not marketing language — it is the finding of the regulatory submissions that got it approved across 50+ countries for stroke, TBI, Alzheimer's disease, and vascular dementia.
This article covers what the clinical evidence actually shows, the practical dosing reality for biohacking applications, and what users should realistically expect.
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and amino acids derived from purified porcine brain proteins. It contains active peptides that cross the blood-brain barrier and exert neurotrophic effects — they promote neuronal survival, axonal growth, synaptogenesis, and protection against neurotoxic insults.
Its neurotrophic effects are mediated primarily through BDNF (brain-derived neurotrophic factor), NGF, and GDNF pathway activation. In clinical settings, these effects have translated to measurable improvements in cognitive function, recovery speed after brain injury, and slowing of neurodegeneration.
The CARS trial (Cochrane-level evidence) showed statistically significant improvements in cognitive function in Alzheimer's patients compared to placebo over 28 weeks. Multiple TBI trials show accelerated recovery of cognitive function and neurological outcomes.
Clinical dosing for neurological indications is substantially higher than what most biohackers use:
Stroke/TBI acute: 30–50mL IV daily for 10–21 days
Alzheimer's (maintenance): 5–10mL IV or IM, 10-day cycles, quarterly
Vascular dementia: 10–30mL IV daily for 20 days
For cognitive enhancement in healthy individuals, the data is thinner — there are no large RCTs in healthy populations by design. Extrapolating from mechanistic data and the clinical evidence, the practical biohacking approach is:
Cognitive enhancement cycles: 5–10mL IM or IV, daily for 10–20 days, 2–4 times per year
The subcutaneous route is used by some practitioners; efficacy appears lower than IM/IV due to absorption kinetics, but it is an option for self-administration where IM is not practical.
IV (intravenous): Highest bioavailability and CNS penetration. Requires medical supervision. Doses above 5mL should be diluted in 100–250mL saline and infused over 30–60 minutes. Slow infusion matters — rapid administration increases the risk of vasomotor reactions (warmth, flushing).
IM (intramuscular): Practical for self-administration. 5–10mL per injection is the standard. Deltoid, vastus lateralis, or gluteal injection sites. Can be administered without medical supervision in most jurisdictions that allow self-injection.
SC (subcutaneous): Lower bioavailability, slower absorption. 2–5mL is the practical upper limit at any single injection site due to volume tolerance. Used when IM is not accessible.
Standard cognitive enhancement cycle:
10mL IM daily × 10 days
Off for 6–12 weeks
Repeat 2–4 times per year
Extended optimization cycle:
5mL IM daily × 20 days
Off for 8–12 weeks
Repeat 2–3 times per year
Neurological recovery protocol (post-injury, high-demand):
10–20mL IV daily × 10 days (supervised)
10mL IM × 10 more days
Off 8 weeks
Reassess
During the cycle (days 1–10):
Most users report increased mental clarity and focus beginning day 3–5. Some experience mild fatigue in the first few days — this is common and typically resolves. Sleep quality often improves during cycles due to the effects on GABA-mediated processes.
Post-cycle (weeks 2–8):
The neurotrophic effects are cumulative and do not disappear when the compound is stopped. Many users report that the most notable cognitive improvements manifest 2–4 weeks after the cycle ends, as synaptic remodeling effects accumulate. This is consistent with the neuroplasticity timeline in the research.
Across multiple cycles:
The benefit-per-cycle relationship appears to compound. Users who complete 4+ cycles per year over multiple years report the most significant long-term cognitive outcomes. This aligns with the neurotrophic model — sustained support for neuronal health has cumulative structural effects.
Cerebrolysin stacks well with:
For the complete protocol including sourcing guidance, injection technique, the full cognitive stack, and the neurological recovery application, see the Cerebrolysin Protocol PDF and the Cognitive Enhancement Protocol.
CerebrolysinNeuropeptidesCognitive EnhancementBDNFNeuroplasticity